A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP)
Phase of Trial: Phase IV
Latest Information Update: 31 May 2016
Price : $35 *
At a glance
- Drugs Ceftaroline fosamil (Primary) ; Ceftriaxone; Vancomycin
- Indications Community-acquired pneumonia; Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions
- Sponsors Actavis; Forest Laboratories
- 31 May 2016 Results published in Allergan media release.
- 31 May 2016 According to Allergan media release, the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil), new indications for pediatric patients 2 months of age to less than 18 years of age with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) caused by Streptococcus pneumoniae and other designated susceptible bacteria.
- 13 Apr 2016 Results published in the Pediatric Infectious Disease Journal